Table 5.

The comparison between the CROSS and NEOCRTEC5010 studies

Parameter	CRSOSS	NEOCRTE 5010
number of patients	368	451
patient inclusion	esophageal adenocarcinoma (75%) and squamous cell carcinoma (25%)	esophageal squamous cell carcinoma (100%)
chemotherapy regimen	Carboplatin + Paclitaxel	vinorelbine + Cisplatin
radiation dose	41.4 Gy/23F	40 Gy/20F
radiation technique	three-dimensional conformal	three-dimensional conformal
photon energies	equal to or greater than 6 MV	6-8MV
GTV	the primary tumor and any enlarged regional lymph nodes	primary tumor and any enlarged regional lymph nodes
CTV	a 1.5 cm radial margin around the GTV	a proximal and distal margin of 3 cm and a 0.5- to 1.0-cm radial margin around the GTV
PTV	a proximal and distal margin of 4 cm, in case of tumor extension into the stomach, a distal margin of 3 cm will be chosen	an 8-mm margin of the clinical target volume
primary endpoint	OS	OS
pCR rate	29%	43.2%
median DFS	23 months	100.1 months
OS results	47% at 5 years	59.9% at 5 years

Abbreviations: GTV gross tumor volume, CTV clinical target volume, PTV planning target volume, OS overall survival, DFS disease-free survival, pCR pathological complete response